Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.43 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.43 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.43 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | F13A1 | P00488 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL3790029 | 0.84 | KDM4E (0.49) | ALDH1A1KDM4EL3MBTL1PLAAT3PLAAT5 | |
| SCHEMBL31130 | 0.83 | L3MBTL1 (0.44) | KDM4EL3MBTL1POLB | |
| Methacrylic Acid SCHEMBL4419898 | 0.81 | L3MBTL1 (0.41) | KDM4EL3MBTL1HTTPOLB | |
| SCHEMBL138809 | 0.77 | KDM4E (0.44) | KDM4EL3MBTL1KMT2APOLB | |
| SCHEMBL6135253 | 0.76 | NPC1 (0.61) | ALDH1A1KDM4ELMNASMN1; SMN2NPC1 | |
| SCHEMBL28063078 | 0.76 | NAAA (0.64) | LMNASMN1; SMN2NPC1RAB9APOLB | |
| Phenol SCHEMBL28117778 | 0.76 | TGM2 (0.56) | ALDH1A1HTTLMNAHSD17B10CCR3 | |
| Phenol SCHEMBL29135387 | 0.76 | CYP2C19 (0.62) | ALDH1A1HTTLMNAHSD17B10CYP2C19 | |
| SCHEMBL29420323 | 0.76 | BCHE (0.53) | ALDH1A1KDM4ELMNACYP2C19SMN1; SMN2 | |
| SCHEMBL8218361 | 0.76 | KDM4E (0.48) | KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109879839-A | 6-piperazinemethyl-7-hydroxybenzofuran compound and medical application thereof | 沈阳大学 | 2019-06-14 | — | — | CN | claimed |
| CN-114805365-B | Factor XIA new macrocycles carrying non-aromatic P2' groups | 百时美施贵宝公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-118344363-A | Tricyclic fused ring derivatives and uses thereof | 广东东阳光药业股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-113329792-B | Substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-115190815-B | Arylcyclohexylamine derivatives and their use in the treatment of psychotic disorders | 吉尔伽美什制药公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118201924-A | Heterocyclic compounds and their use | 万特斯治疗美国公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118164961-A | 4-Methylsulfonyl substituted piperidine urea compounds for the treatment of Dilated Cardiomyopathy (DCM) | 迈奥卡迪亚公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-114502531-B | Process for preparing plasma kallikrein inhibitors | 雷佐鲁特公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118076605-A | Substituted 1H-pyrazolo [4,3-c ] quinolines, methods of preparation and uses thereof | 洛蒙治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118063445-A | Pyrrolidine amide derivatives and use thereof | 广东东阳光药业股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-08 | — | — | US | disclosed |
| WO-2005079779-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-01 | — | — | WO | disclosed |
| EP-1556019-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | Merz Pharma GmbH & Co. KGaA (DE) | 2005-07-27 | — | — | EP | disclosed |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | FOREST LABORATORIES, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2004098516-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | disclosed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | disclosed |
| EP-1294377-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOLISM AND ALCOHOL DEPENDENCE | Cardiff and Vale National Health Service Trust (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002002091-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOLISM AND ALCOHOL DEPENDENCE | CARDIFF & VALE NATIONAL HEALTH SERVICE TRUST (GB) | 2002-01-10 | — | — | WO | disclosed |
| CN-1202893-A | Novel isoxazoline and isoxazole fibrinogen receptor antagonists | DU PONT MERCK PHARMA (US) | 1998-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | APP, BACE1, PSEN1 | ALDH1A1 2630/4885KDM4E 2202/4885L3MBTL1 2532/4885 |
| US-20050197361-A1 | Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders | GRM5, GRIK5, GRIN2C | ALDH1A1 1519/4885KDM4E 2508/4885L3MBTL1 944/4885 |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | ACHE, BACE1, CHRNA5 | ALDH1A1 1726/4885KDM4E 3278/4885L3MBTL1 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.